Search details
1.
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Blood
; 137(1): 49-60, 2021 01 07.
Article
in English
| MEDLINE | ID: mdl-32693406
2.
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Lancet Oncol
; 11(10): 934-41, 2010 Oct.
Article
in English
| MEDLINE | ID: mdl-20739218
Results
1 -
2
de 2
1
Next >
>>